The FDA’s latest warning wave reinforces ongoing scrutiny of telehealth and pharma promotions.

Hims & Hers’ former partner plans to continue copycat GLP-1 sales even as FDA investigations and patent lawsuits raise the risks.

New studies show the limitations of relying on AI tools for health answers. Platforms must tighten safeguards and educate users on smart prompting.

It’s unlikely to pull users from ChatGPT, but it could increase pressure on tech giants to safeguard user data and avoid overhyping their AI’s medical advice capabilities.

Chatbots and creators become go-to mental health supports for Gen Z as barriers to traditional care persist.

Most Americans are wary of AI, but regular users show far higher trust, proving comfort grows with experience.

Brands selling health supplements need transparency around their claims, or doctors won’t recommend them to patients.

Data shows the first decline in obesity rates in US adults, but children and teens moved in the opposite direction.

The retailer is sidestepping in-person medical care and insurance complexities in hopes of turning pharmacy traffic into weight loss drug customers.

Two-thirds of clinicians stop engaging with content after clunky interactions.

Drugmakers’ price drops don’t affect all patients the same. Brands and marketers must decode cost complexities where patients already seek out weight loss advice, like on social media.

New AI capabilities add clinician-vetted, empathetic guidance for women—the predominant segment of its user base.

Videos backed by thin evidence rack up views on YouTube, raising stakes for stricter creator guidelines.

Its pharma ad lawsuit against J&J’s promotions lands amid rising enforcement and shrinking tolerance for bold claims.

The offering lets employers subsidize employees’ cash-pay price—sidestepping opaque PBM rebates and helping rein in rising pharmacy costs.

Rising legal and regulatory scrutiny of compounded weight loss drugs suggests branded pharma ties are the safer avenue for telehealth players to sell their copycat GLP-1s.

Novo’s drug candidate CagriSema lagged Lilly’s Zepbound in weight loss trials, sending Novo shares down 15% and widening Lilly’s market lead.

Quicker, reliable AI notes help clinicians reclaim minutes they can spend on patients, even as AI accuracy concerns persist.

Tragic news moves consumers’ health choices, signaling to healthcare marketers that they need to pay attention to key cultural moments, not just paid celebrity endorsements.

Justices curb Trump’s tariffs, but a national security case could sustain pharma import taxes.